We are live on ! Find out more
INDP icon

Indaptus Therapeutics

3.17 USD
+0.02
0.63%
At close Updated Nov 13, 4:00 PM EST
Pre-market
After hours
3.23
+0.06
1.89%
1 day
0.63%
5 days
-2.46%
1 month
32.64%
3 months
199.06%
6 months
81.14%
Year to date
15.69%
1 year
7.09%
5 years
-98.32%
10 years
-99.97%
 

About: Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.

Employees: 5

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 0%
Neutral 100%
Negative 0%
Neutral
GlobeNewsWire
2 days ago
Indaptus Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
NEW YORK, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a biotechnology company dedicated to immunotherapy research, today announced financial results for the third quarter and nine months ended September 30, 2026, and provided a corporate update. Junyi Dai, Indaptus Therapeutics' Chief Executive Officer and Chairman of the Board, commented, “Our strategic objective is to position Indaptus for its next phase of growth by actively pursuing innovative opportunities with significant long-term potential and expanding the Company's strategic focus into promising areas of medical innovation. We believe the successful completion of our approximately $24.0 million private placement provides an important foundation to advance this vision, giving us the financial resources and strategic flexibility to explore new opportunities and build long-term shareholder value.
Indaptus Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Neutral
GlobeNewsWire
3 months ago
Indaptus Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company"), a biotechnology company dedicated to immunotherapy research, today announced financial results for the second quarter and six months ended June 30, 2026, and provided a corporate update.
Indaptus Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Neutral
GlobeNewsWire
5 months ago
Abbott Cooper PLLC Announces Investigation on Behalf of Indaptus Therapeutics, Inc. Stockholders
STAMFORD, Conn., June 17, 2026 (GLOBE NEWSWIRE) -- Abbott Cooper PLLC is investigating potential legal claims on behalf of stockholders of Indaptus Therapeutics, Inc. (Nasdaq: INDP) who held their shares prior to December 22, 2025.
Abbott Cooper PLLC Announces Investigation on Behalf of Indaptus Therapeutics, Inc. Stockholders
Neutral
GlobeNewsWire
6 months ago
Indaptus Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical-stage biotechnology company, today announced financial results for the first quarter ended March 31, 2026, and provided a strategic corporate update. Junyi Dai, Indaptus Therapeutics' Chief Executive Officer and Chairman of the Board, commented, “Following recent changes in executive management, the Company has conducted a review of its development programs, operating resources and ongoing corporate initiatives.
Indaptus Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Neutral
GlobeNewsWire
10 months ago
Indaptus Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar
NEW YORK, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announces it has entered into a $6 million securities purchase agreement with investor, David E. Lazar, for the purchase of non-voting convertible preferred stock of the Company. Mr. Lazar has been appointed Indaptus' Co-Chief Executive Officer and Chairman of the Board. Jeffrey Meckler will continue as Co-CEO and remain on the Board.
Indaptus Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar
Neutral
GlobeNewsWire
12 months ago
Indaptus Therapeutics Chief Scientific Officer Dr. Michael Newman to Present at the Donor Selection & Cell Source Summit
NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced that Michael Newman, Ph.D., Founder and Chief Scientific Officer, will present at the 3rd Donor Selection & Cell Source Summit, taking place November 19–20, 2025, in San Diego, California.
Indaptus Therapeutics Chief Scientific Officer Dr. Michael Newman to Present at the Donor Selection & Cell Source Summit
Neutral
GlobeNewsWire
1 year ago
Indaptus Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announces financial results for the third quarter ended September 30, 2025, and provides a corporate update. Jeffrey Meckler, Indaptus Therapeutics' Chief Executive Officer, commented, “We have completed the Safety Lead-In cohort, dosing six evaluable participants with the combination of Decoy20 and tislelizumab.
Indaptus Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Neutral
GlobeNewsWire
1 year ago
Indaptus Therapeutics Provides Clinical Update
Decoy20 monotherapy induces Partial Response in patient with urothelial cancer and liver metastases Decoy20 combination with PD-1 inhibitor, tislelizumab, demonstrates safety profiles consistent with each agent NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announces recent updates for the ongoing INDP-D101 clinical trial.
Indaptus Therapeutics Provides Clinical Update
Neutral
GlobeNewsWire
1 year ago
Indaptus Therapeutics to Present at the H.C. Wainwright 27ᵗʰ Annual Global Investment Conference
NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) announced today that Jeffrey A.
Indaptus Therapeutics to Present at the H.C. Wainwright 27ᵗʰ Annual Global Investment Conference
Neutral
GlobeNewsWire
1 year ago
Indaptus Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Company Initiates Combination Trial and Strengthens Balance Sheet to Support Continued Clinical Progress Company Initiates Combination Trial and Strengthens Balance Sheet to Support Continued Clinical Progress
Indaptus Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Price charts implemented using Lightweight Charts™